ObsEva SA

05.03.2024

Business wind down and take off for listed Swiss startups (startupticker.ch)

25.11.2022

Obseva sells rights to its preterm labor treatment for up to $115 million (startupticker.ch)

24.08.2022

Swiss biotechs in dispute with regulators (startupticker.ch)

20.06.2022

Obseva receives its first European Marketing Authorization (startupticker.ch)

06.01.2022

ObsEva announces positive results from Phase 3 trials (startupticker.ch)

05.08.2021

ObsEva receives USD 500 million in upfront and milestone payments (startupticker.ch)

10.11.2020

Startups under new leadership (startupticker.ch)

08.08.2019

ObsEva secures $75 million non-dilutive financing (startupticker.ch)

13.07.2018

ObsEva with a positive start at Swiss Exchange (startupticker.ch)

01.03.2018

ObsEva Reports Positive Phase 3 Results (startupticker.ch)

02.03.2017

Eclosion: Incubator for market stars in Geneva (startupticker.ch)

26.01.2017

ObsEva goes public (startupticker.ch)

18.01.2017

ObsEva Expands Leadership Team as it prepares for IPO (startupticker.ch)

31.10.2016

ObsEva announces IPO and Phase 3 clinical trials (startupticker.ch)

04.08.2016

ObsEva: Fifth compound in a clinical program (startupticker.ch)

25.02.2016

How to raise CHF100 million (startupticker.ch)

24.11.2015

ObsEva Closes CHF 60 Million in Series B Financing (startupticker.ch)

11.09.2015

ObsEva presents encouraging results of the pharmacology studies (startupticker.ch)

03.03.2015

ObsEva Reports Positive Phase 1 Results for Its Lead Compound Treating Preterm Labour (startupticker.ch)

28.11.2014

ObsEva Announces Initiation of a Pivotal Phase 2 Study (startupticker.ch)